阿立哌唑与利培酮治疗精神分裂症的对照研究

Comparative study of Aripiprazole and Risperridone for schizophrenia

目的:观察阿立哌唑的疗效及安全性。方法:采用随机、单盲、对照的设计原则将64例精神分裂症患者分为阿立哌唑组与利培酮组,疗程为4周。在治疗前、治疗1、2、4周采用PANSS量表评定疗效,TESS量表、实验室检查及体检评定安全性。结果:两组总体疗效相当,阿立哌唑对以阴性症状为主要表现的患者疗效优于利培酮组。不良反应:锥体外系反应利培酮组明显高于阿立哌唑组(P<0.01)。结论:阿立哌唑治疗以阴性症状为主的精神分裂症的疗效、耐受性及依从性均较好。

Objective： To verify the efficacv and side effects of Aripiprazole on schizophrenia. Method： Patients who met CCMD - 3 criteria for schizophrenia were randomized into two groups ： Aripiprazole group and Risperidone group in a case - control study. The treatment duration was 4 weeks. The PANSS, TESS, related lab tests and physical examination were employed for assessing the treatment effectiveness and side effects. Result： At the end of treatments,the scores of the PANSS at the end of 4 weeks had no significant difference between the two groups. The patients with positive symptoms had a poor efficacy in Aripiprazole group than that in Risperidone group, while patients with negative symptoms had a better efficacy in Aripiprazole group than in Risperidone group. And patients used Aripiprazole had fewer side effects than those in Risperidone group, especially in the items of reduced external pyramidal syndrome （EPS）. Conclusion： Aripiprazole has a better efficacy to schizophrenia patients with more negative symptoms and has a good tolerance and compliant.